Today: 20 May 2026
$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears
13 November 2025
3 mins read

German Stock Market Today, 13 Nov 2025: DAX Closes 1.39% Lower at 24,041 as Siemens Slumps; Merck Rises, Allianz Lifts Guidance

Germany’s blue‑chip DAX retreated on Thursday as a heavy sell‑off in Siemens outweighed pockets of strength in healthcare and defense. At the Xetra close, the DAX finished down 1.39% at 24,041.62, its sharpest one‑day percentage drop since Oct. 17, 2025. The broader STOXX 600 also slipped, with investors pivoting to incoming U.S. macro data after Washington’s shutdown ended.

Market snapshot

  • DAX: 24,041.62 (‑1.39%), with intraday pressure building into the close.
  • STOXX 600: closed ‑0.6% at 580.67; Germany lagged peers as industrials fell.
  • Winners/losers:Merck KGaA +4.9%, Renk +7.2%, while Siemens −9.4% after results and portfolio news.

Siemens-led sell‑off drags Frankfurt lower

Siemens shares tumbled after the company posted a mixed fiscal Q4—industrial profit and net income came in below consensus—even as full‑year free cash flow and sales were strong. The group also unveiled plans to deconsolidate Siemens Healthineers, reducing its stake from about 67% to ~37% via a direct share spin‑off to Siemens AG investors, a move pitched as sharpening focus on automation, software and mobility. The earnings miss and “spin‑off math” prompted profit‑taking across industrials. Reuters+2Reuters+2

Siemens’ official press release confirmed the intended 30% distribution of Healthineers shares to Siemens AG shareholders, subject to regulatory and shareholder approvals, with more details expected in early Q2 2026. Management reiterated a progressive dividend policy for Siemens after deconsolidation.


Bright spots: Merck beats; Deutsche Telekom and BASF deliver headlines; Allianz turns upbeat

Merck KGaA advanced after reporting a Q3 earnings beat, driven by life sciences and semiconductor‑linked demand. The company confirmed 2025 guidance, with the stock among the DAX’s top performers.

Deutsche Telekom nudged guidance higher as Q3 EBITDA AL landed broadly in line with company‑pooled expectations, keeping telecoms resilient amid the industrial sell‑off.

BASF added medium‑term corporate intrigue: it formalized plans to list its Agricultural Solutions unit in Frankfurt as a European company (SE) by 2027 and named a new management board for the business—another step in the portfolio’s streamlining.

Late in the session, Allianz raised its full‑year 2025 operating‑profit guidance to €17.0–€17.5 billion after strong nine‑month operating results (€13.1 billion), providing an offset to rate‑sensitive financials. The firm is slated to report detailed Q3 figures on Friday, 14 Nov.

Defense names were mixed, though the tape stayed news‑heavy around the sector: German budget committee approval for the 2026 defense budget and special‑fund plan underscored ongoing procurement momentum that has supported Rheinmetall this year.


Macro drivers: soft euro‑area output, firmer Bund yields, and a U.S. data deluge ahead

Fresh Eurostat figures showed euro‑area industrial production up 0.2% m/m in September (1.2% y/y), softer than expected, with Ireland’s swing again distorting the aggregate. Germany’s component improved, but the headline disappointed.

In rates, 10‑year Bund yields edged higher (≈2.65%–2.68%), reflecting firmer global yields and attention to upcoming U.S. releases that could re‑anchor Federal Reserve expectations—a backdrop that often pressures equity valuations for duration‑sensitive names.

Policy chatter added color: Bundesbank chief Joachim Nagel—an ECB Governing Council member—kept central‑bank succession talk in the headlines in a Spiegel interview, though the near‑term rate stance remains data‑dependent per recent ECB communications.


Stock‑by‑stock highlights

  • Siemens (SIE): Q4 industrial profit of €3.19 bn missed the company‑compiled consensus; sales rose 6% on a comparable basis. Shares were the day’s major drag on the DAX.
  • Siemens Healthineers (SHL): Set to see free float increase if Siemens completes the planned spin‑off of 30% of shares to Siemens AG investors.
  • Merck KGaA (MRK GY): Q3 EBITDA €1.67 bn vs. €1.56 bn expected; stock rallied.
  • Renk (R3NK): Gained after confirming full‑year guidance, part of a defense‑heavy tape.
  • Deutsche Telekom (DTE): Slightly below Q3 core‑profit expectations but lifted full‑year outlook.
  • Infineon (IFX): A day after results, management raised 2026 sales ambitions for AI‑power markets while staying cautious on autos; shares were little changed today.
  • BASF (BAS): Progressed its Agricultural Solutions separation/IPO path and leadership; timetable points to a 2027 listing.

Why it matters

The combination of company‑specific shocks (Siemens’ outlook and portfolio reshape) and macro uncertainty (euro‑area output softness, higher Bund yields, and a looming U.S. data backlog now that Washington has reopened) created a risk‑off bias in Frankfurt. That mix typically penalizes cyclicals and long‑duration industrials more than healthcare and defense, which is precisely how the DAX factor map printed today.


What’s next

  • Friday, 14 Nov: Allianz Q3 report and webcast; investors will parse underwriting trends and capital returns after today’s guidance lift.
  • ECB publications & speakers: This week’s Economic Bulletin (Issue 7/2025) and recent Governing Council commentary keep the policy debate live as markets watch inflation drift toward 2%.
  • U.S. data catch‑up: A wave of delayed releases could whipsaw global rates and equities; Frankfurt will feel the spillovers.

Bottom line

Berlin’s market closed decisively lower as Siemens’ slide set the tone, but Merck’s beat and Allianz’s guidance hike showed not all corporate news is pointing south. With Bund yields creeping up and euro‑area output underwhelming, the DAX enters Friday focused on insurer earnings and the incoming U.S. data dump that could reset risk appetite into next week.

Sources: market closes and intraday sector moves from Reuters and exchange/market data providers; company results and statements from corporate releases and wire services, all dated Nov. 13, 2025 unless otherwise noted.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance
Previous Story

NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance

Micron (MU) Stock Skyrockets to Record High on AI Frenzy – Analysts See More Upside
Next Story

Micron Technology Stock Falls 3% as Morgan Stanley Hikes Target and New Auto Chip Launches — November 13, 2025

Go toTop